Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest
Health care companies and health plans called their final witnesses Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal...To view the full article, register now.
Already a subscriber? Click here to view full article